Postoperative thrombotic events following major surgery in patients with a history of COVID-19: a retrospective cohort analysis of commercially insured beneficiaries in …
DV Lazzareschi, Y Luo, N Fong, J Boscardin… - Canadian Journal of …, 2024 - Springer
Purpose We sought to evaluate the synergistic risk of postoperative thrombosis in patients
with a history of COVID-19 who undergo major surgery. Major surgery and SARS-CoV-2 …
with a history of COVID-19 who undergo major surgery. Major surgery and SARS-CoV-2 …
Venous thromboembolism and major bleeding in severe and critical COVID-19 hospitalized patients
V Abate, A Vergatti, A Casoria… - … Archives for Chest …, 2024 - monaldi-archives.org
Venous thromboembolism (VTE) and major bleeding (MB) are life-threatening complications
described in COVID-19 hospitalized patients and they can be considered as two sides of the …
described in COVID-19 hospitalized patients and they can be considered as two sides of the …
[HTML][HTML] Immunothrombosis and COVID-19‒a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital
CA Lima, FAR Gonçalves, BAMP Besen, AJR Pereira… - Clinics, 2023 - SciELO Brasil
Highlights VTE COVID-19 patients were sicker, their hospital stay was longer, and they were
more likely to die. VTE incidence is still considerable in COVID-19 patients even under …
more likely to die. VTE incidence is still considerable in COVID-19 patients even under …
Contribution of genetics and lifestyle to the risk of major cardiovascular and thromboembolic complications following COVID-19
Clinical determinants for cardiovascular and thromboembolic (CVE) complications of COVID-
19 are well-understood, but the roles of genetics and lifestyle remain unknown. We …
19 are well-understood, but the roles of genetics and lifestyle remain unknown. We …
[HTML][HTML] A Case Report of Disseminated Thromboses and Cardiac Ischemia in a Patient With COVID-19 Pneumonia
NA Guevara, L Rakovica, H Pleitez, MMF Chang… - Cureus, 2023 - ncbi.nlm.nih.gov
The novel coronavirus disease (COVID-19) pandemic caused by the SARS-CoV-2 virus
started in December 2019 in the city of Wuhan, in China's Hubei province. This virus quickly …
started in December 2019 in the city of Wuhan, in China's Hubei province. This virus quickly …
[HTML][HTML] Treated post-acute sequelae after COVID-19 in a German matched cohort study using routine data from 230,256 adults
D Müller, S Stengel, M Roesler, G Schillinger… - Frontiers in …, 2023 - frontiersin.org
Background Post-acute sequelae after COVID-19 are still associated with knowledge gaps
and uncertainties at the end of 2022, eg, prevalence, pathogenesis, treatment, and long …
and uncertainties at the end of 2022, eg, prevalence, pathogenesis, treatment, and long …
[HTML][HTML] The Outcome of Left Ventricular Thrombosis in Patients with Coronavirus Disease 2019 Infection
M Karvandi, A Sheidary, KH Ahrami - International Journal of …, 2024 - brieflands.com
Background: Left ventricular thrombus (LVT) is a significant cardiovascular complication in
patients with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory …
patients with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory …
A very rare combination of venous and arterial thrombosis in a patient with COVID-19
H El Malki, Y Morjane, A Belarbi, MT Berkane… - Annales de Cardiologie …, 2024 - Elsevier
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. This epidemic has
caused serious socio-economic problems worldwide, with a very high mortality rate. Several …
caused serious socio-economic problems worldwide, with a very high mortality rate. Several …
[PDF][PDF] Cardiac Arrest Secondary to Inferior ST-Segment-Elevation Myocardial Infarction in Patient with Paroxysmal Nocturnal Hemoglobinuria and COVID-19 Infection
Patients with paroxysmal nocturnal hemoglobinuria (PNH) have transient attacks of
complement-mediated hemolysis and thrombosis that can be spontaneous or secondary to …
complement-mediated hemolysis and thrombosis that can be spontaneous or secondary to …
High-risk subgroups were not identified to benefit from thromboprophylaxis after hospitalization for COVID-19
L Baumann Kreuziger, T Kwon, RS Kasthuri, L Wahid… - 2024 - vtechworks.lib.vt.edu
Background: The Accelerating COVID-19 Therapeutic Interventions and Vaccines-4c (ACTIV-
4c) trial investigated prophylactic apixaban for 30 days following hospitalization for COVID …
4c) trial investigated prophylactic apixaban for 30 days following hospitalization for COVID …